Shenzhen Wingor Biotechnology Co., Ltd., a leading Chinese stem cell and gene therapy company, announced it has raised tens of millions in CNY funding in a financing round led by KC Eternium Management, an affiliate of Globelink Holding specializing in biopharmaceutical investments and overseas resource integration.
The funding will support Wingor's advancement of its comprehensive cell therapy pipeline and international expansion efforts. KC Eternium Management's Chief Investment Officer Kent Cai stated, "We believe that Wingor Biotechnology is a representative enterprise with strong verticalized capabilities from leading technologies and research to production and commercialization capabilities. Through this collaboration, we hope to support Wingor's rapid development and empower deep international cooperations through exporting Wingor's leading treatments globally."
Multi-Platform Therapeutic Approach
Founded in 2013, Wingor Biotechnology has established itself as a nationally renowned high-tech enterprise with strategic positioning across six major industry sectors: drug research and development, cell storage, cell CDMO, cell-based medical aesthetics, health management, and education. The company operates a dual-track industrialization model combining innovative drug IND applications and investigator-initiated trials, maintaining more than ten research and development pipelines.
The company's therapeutic platforms demonstrate significant progress across multiple areas. The stem cell platform leads southern China in the number of IND applications accepted for four stem cell drugs. The exosome platform has completed PCC screening for its first exosome-conjugated small nucleic acid drug, while the immune cell platform is advancing clinical development of W-iNKT therapy targeting solid tumors. Additionally, the gene engineering+ platform explores cross-platform technology integration through technical cooperation with MIT.
Clinical Development and Hospital Partnerships
Wingor has established long-term cooperative relationships with more than 60 top-tier hospitals in China, collaborating on more than ten cell therapy clinical research projects. Currently, four projects have received approval and begun patient recruitment. The company participates as a cell supplier in the "14th Five-Year Plan" national key project, specifically Special Project 1: Stem Cell Therapy for Liver Failure in partnership with the Chinese People's Liberation Army General Hospital.
Addressing Unmet Medical Needs
The company's focus addresses significant unmet clinical needs in neurological diseases and degenerative diseases. Stem cell therapy represents a pioneering frontier in regenerative medicine, enabling repair and regeneration of damaged tissues at the cellular level. This approach offers personalized and targeted therapies with potentially fewer side effects than traditional methods, accelerating recovery times for conditions including neurodegenerative diseases, autoimmune disorders, diabetes, Parkinson's disease, spinal cord injuries, and organ failure.
Strategic Vision and Future Plans
Wingor continues to deepen its dual-drive strategy of "independent innovation + clinical translation" through collaborative efforts with its clinical network of top-tier hospitals and international application channels. The current financing round remains open, with the company welcoming additional investors with synergistic capabilities to join in driving the development and value realization of leading cell therapy technologies.
The company aims to create a closed-loop for the entire cell industry chain and build a comprehensive cell therapy ecosystem covering R&D, clinical trials, and commercialization to provide breakthrough treatment solutions accessible to patients worldwide.
